Vitamin D and Demyelinating Diseases: Neuromyelitis Optica (NMO) and Multiple Sclerosis (MS).
Cady RodneySherriann RodneyRichard M MillisPublished in: Autoimmune diseases (2020)
Vitamin D deficiency is prevalent in all ages regardless of climate or geographical location and evidence is emerging that the incidence of autoimmune diseases is increasing worldwide. Women make up a large proportion of autoimmune disease diagnoses, underscoring the importance of fully elucidating the complex synergistic relationships between estrogens and vitamin D. Vitamin D receptor-activating drugs appear to enhance remyelination in patients diagnosed with multiple sclerosis (MS) and other demyelinating diseases such as neuromyelitis optica (NMO). This review is intended to update health practitioners about the potential role of vitamin D deficiency demyelination and to motivate future research on dietary recommendations for vitamin D in preventing and treating demyel1nating diseases.
Keyphrases
- multiple sclerosis
- white matter
- end stage renal disease
- public health
- healthcare
- ejection fraction
- mass spectrometry
- newly diagnosed
- mental health
- climate change
- primary care
- ms ms
- peritoneal dialysis
- prognostic factors
- polycystic ovary syndrome
- human health
- drug delivery
- adipose tissue
- cancer therapy
- metabolic syndrome
- pregnant women
- type diabetes
- drug induced
- breast cancer risk